Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Enterprise ValueMarket Capitalization

Immuneering (IMRX) EBITDA Margin: 2020-2022

Historic EBITDA Margin for Immuneering (IMRX) over the last 3 years, with Dec 2022 value amounting to -2,886,419.34%.

  • Immuneering's EBITDA Margin fell 288070777.00% to -2,886,419.34% in Q4 2022 from the same period last year, while for Dec 2022 it was -15,931.33%, marking a year-over-year decrease of 1431665.00%. This contributed to the annual value of -15,931.33% for FY2022, which is 1431665.00% down from last year.
  • As of Q4 2022, Immuneering's EBITDA Margin stood at -2,886,419.34%, which was down 8,551.21% from -33,364.36% recorded in Q3 2022.
  • Immuneering's EBITDA Margin's 5-year high stood at -644.49% during Q3 2020, with a 5-year trough of -2,886,419.34% in Q4 2022.
  • For the 3-year period, Immuneering's EBITDA Margin averaged around -268,255.47%, with its median value being -1,771.06% (2021).
  • Data for Immuneering's EBITDA Margin shows a maximum YoY crashed of 288,070,777bps (in 2022) over the last 5 years.
  • Over the past 3 years, Immuneering's EBITDA Margin (Quarterly) stood at -877.48% in 2020, then slumped by 483,409bps to -5,711.57% in 2021, then plummeted by 288,070,777bps to -2,886,419.34% in 2022.
  • Its last three reported values are -2,886,419.34% in Q4 2022, -33,364.36% for Q3 2022, and -12,223.67% during Q2 2022.